Case studies

The cases that follow are composites assembled from multiple engagements. They are written to give a clinician, a pharmacy director, or a family a realistic feel for how a named-patient engagement unfolds in practice, without disclosing any single real patient, physician, institution, or outcome. No patient names, physician names, hospital names, dates, or specific outcome metrics are shown. We do not publish individual-case outcomes; the patient is the person to whom that information belongs.

Case 1 — Haematologic oncology: a cell therapy into a Gulf tertiary centre

Composite case. Clinical specifics, geography, and timing have been altered to protect patient privacy. No PHI is shown.

The situation. An adult patient with a relapsed haematologic malignancy had exhausted standard lines of therapy. The treating haematologist at a tertiary centre in the Gulf identified a US-approved autologous cell therapy as the appropriate next step. The therapy was not available at the treating centre and was not yet registered in the country. The family, a US-citizen household ordinarily resident in the region, had the resources to pursue a named-patient route and strongly preferred to keep the patient under the existing clinical team.

The constraint. Autologous cell therapies are logistically complex. They require apheresis under an institutional protocol, a specific return-shipment window, and cold-chain handling that does not tolerate delay at any step. The destination country had an open named-patient pathway for unregistered biologics, but no prior experience at that centre with the specific product, and the ministry authorisation required a medical-rationale package that went beyond what the prescriber's office ordinarily produced.

The coordination posture. Reserve Meds engaged the treating haematologist and the hospital pharmacy director jointly, on a named-account basis. Our regulatory lead drafted the ministry submission and the unregistered-product declaration for the prescriber's signature. Our pharmacist-in-charge at Altima Care coordinated with the US manufacturer's limited-distribution network on the apheresis-to-manufacture-to-return cycle. The family had a single coordinator from intake through delivery.

What we did. We filed the ministry authorisation in the local language and in English. We confirmed the apheresis protocol would be acceptable to the US manufacturer's programme. We arranged the validated cold-chain routing, including the return leg of the cycle, with a carrier qualified for the product's handling profile. We delivered a full DSCSA transaction history and a cold-chain log with the shipment. The hospital pharmacy signed for acceptance without excursion.

The handoff. Administration, monitoring, and follow-up remained with the treating haematologist. We delivered the regulatory file, the dispensing documentation, and the cold-chain record to the hospital pharmacy, and we closed our role at the point of acceptance. We retained the engagement file under our record-retention schedule and remained available to the treating physician's office for any pharmacovigilance correspondence arising from the cycle.

Case 2 — Solid-tumour oncology: a targeted therapy under a personal import

Composite case. Clinical specifics, geography, and timing have been altered to protect patient privacy. No PHI is shown.

The situation. An adult patient with a solid-tumour malignancy carrying a specific molecular alteration was being treated at a private hospital in South Asia. The treating medical oncologist identified a US-approved targeted oral therapy matched to the alteration. The therapy was not registered locally and the hospital pharmacy did not carry it. The patient and family had the means to pursue a personal-import route under the destination country's published pathway for individual patients.

The constraint. Personal-import pathways in the destination country are typically quantity-limited per authorisation and require re-authorisation on a cycle consistent with the therapy's dosing. An oral targeted therapy on a continuous-dosing schedule therefore required a predictable rhythm of authorisation, procurement, and delivery, with no tolerance for a missed cycle.

The coordination posture. Reserve Meds set up a standing file for the patient with the destination-country authority, drafted the initial authorisation on the prescriber's letterhead for signature, and established a cycle cadence that kept the authorisation current ahead of each resupply. The engagement was patient-facing (with the family as the primary client), with the treating oncologist credentialed as the prescriber of record.

What we did. We procured the therapy through a licensed US specialty wholesaler under DSCSA serialisation. We assembled the personal-import authorisation for each cycle and filed it on a schedule that avoided gap-days. We shipped to the treating oncologist's clinic rather than to the home, which the family preferred because it kept dispensing under clinical supervision. We provided a monthly reminder ahead of the next authorisation window so the prescriber did not have to track the calendar.

The handoff. The oncologist remained responsible for dosing, monitoring, and the management of any adverse events. Our role was limited to the regulatory and procurement cycle. On resolution of treatment, we closed the file, retained records under the applicable retention schedule, and remained available to the oncologist's office for any long-tail pharmacovigilance correspondence.

Case 3 — Rare-disease gene therapy: a single-administration product into a hospital formulary

Composite case. Clinical specifics, geography, and timing have been altered to protect patient privacy. No PHI is shown.

The situation. A paediatric patient with a rare genetic disease had been evaluated as eligible for a US-approved single-administration gene therapy. The treating clinician was a consultant at a specialised centre in the Middle East. The therapy was not registered in the country and had not previously been administered at the centre, though a peer centre had completed a prior administration through a named-patient authorisation.

The constraint. Single-administration gene therapies combine a high logistical burden (frozen shipping, narrow administration window, and a one-chance character) with a high regulatory burden (ministry authorisation, hospital P&T sign-off, and manufacturer programme enrolment). The family and the treating centre needed the whole sequence choreographed, because a failure at any step could not be recovered within the patient's clinical window.

The coordination posture. Reserve Meds engaged at the institutional level with the hospital pharmacy director and the treating clinician in parallel. We managed the manufacturer programme enrolment on the US side and the ministry authorisation on the destination side. Our regulatory lead ran the dependency map across the two jurisdictions so that no authorisation was opened before a preceding step was confirmed.

What we did. We secured the manufacturer programme slot. We prepared the ministry authorisation in both languages and supported the institution's quality office in reviewing the manufacturer's handling requirements against the hospital's receiving SOP. We arranged frozen-chain shipping with embedded monitoring and a qualified on-the-ground agent to escort the shipment through the airport handover. The shipment arrived within the administration window and with no excursion.

The handoff. Administration was performed by the treating clinical team. Our role closed at the moment of acceptance by the hospital pharmacy. We retained the engagement file under the applicable retention schedule, and we supported the hospital pharmacy with any follow-up documentation requested by the ministry as part of the post-administration reporting.

Case 4 — Rare-disease enzyme-replacement therapy: a multi-year cycle

Composite case. Clinical specifics, geography, and timing have been altered to protect patient privacy. No PHI is shown.

The situation. An adult patient with a rare lysosomal storage disorder had been stable on a US-approved enzyme-replacement therapy at a European centre for several years and had subsequently relocated to a Middle Eastern city for family reasons. The therapy was not available in the new country of residence and a treatment interruption was not acceptable on clinical grounds.

The constraint. Enzyme-replacement therapies are administered on a regular cycle, are cold-chain sensitive, and are typically supplied through a limited-distribution manufacturer programme. The primary risk was the gap between arrival in the new country and a first successful named-patient shipment; a missed cycle of weeks could translate into clinical regression that was difficult to recover.

The coordination posture. Reserve Meds opened the engagement well in advance of the patient's relocation, in parallel with the European centre's handover to the new treating physician. We sequenced the ministry authorisation, the manufacturer programme transfer, and the first US procurement so that the first dose in the new country landed within the patient's planned infusion window.

What we did. We credentialed the new treating physician, filed the ministry authorisation, and enrolled the patient in the US manufacturer's named-patient programme under the new prescriber of record. We procured the first cycle through our licensed US wholesaler on a schedule that left contingency for any customs delay on the destination side. We established a standing cycle cadence, with authorisation renewal scheduled ahead of each shipment. We arranged cold-chain delivery to the new treating centre's outpatient infusion unit.

The handoff. Clinical care transferred cleanly to the new treating physician. The European centre retained a consultative role on request of the family. Reserve Meds has carried the cycle on a standing cadence, with periodic reviews of the authorisation and procurement sequence against any changes in either the US or the destination-country regulatory posture.

Case 5 — Paediatric neuromuscular: a disease-modifying therapy under a named-patient authorisation

Composite case. Clinical specifics, geography, and timing have been altered to protect patient privacy. No PHI is shown.

The situation. A paediatric patient with a neuromuscular disease had been identified as eligible for a US-approved disease-modifying therapy that was not yet registered in the country of residence. The family was supported by a paediatric neurologist at a specialist centre and had been in discussion with a peer family who had previously accessed the therapy through a named-patient authorisation in a neighbouring country.

The constraint. The therapy was administered at a tertiary hospital rather than in an outpatient setting. The named-patient authorisation was available in principle, but required a medical-rationale dossier that went beyond the prescriber's ordinary documentation and, in the paediatric setting, a formal parental consent countersigned by the treating physician. The clinical timing was sensitive; for this disease class, earlier administration is associated with better functional preservation, and a month of process delay had real clinical meaning.

The coordination posture. Reserve Meds engaged the paediatric neurologist and the hospital pharmacy in parallel, with the family's coordinator kept in the loop on timing. We treated this as a time-critical engagement and prioritised it on our internal queue accordingly. Our regulatory lead drafted the medical-rationale dossier from the prescriber's notes, for the prescriber to review and sign, rather than asking the prescriber to assemble the dossier from a blank page.

What we did. We filed the named-patient authorisation and the paediatric consent in parallel with the US procurement, rather than in sequence, to compress the elapsed time. We procured the therapy through a licensed US specialty wholesaler under DSCSA serialisation. We delivered to the hospital pharmacy in validated cold-chain packaging with embedded temperature logging; the receiving pharmacy accepted without excursion. We provided the hospital quality office with the full regulatory and sourcing file for its records.

The handoff. Administration and follow-up were managed by the treating neurologist and the hospital's multidisciplinary paediatric team. We closed our role at pharmacy acceptance and have remained available for any subsequent pharmacovigilance correspondence or for future cycles should the treating physician request.

Case 6 — Autoimmune biologic: an individual patient into a private hospital system

Composite case. Clinical specifics, geography, and timing have been altered to protect patient privacy. No PHI is shown.

The situation. An adult patient with an advanced autoimmune condition had been cycled through several available biologics without sustained response, and the treating rheumatologist identified a US-approved newer-generation biologic as the appropriate next line. The therapy was approved in the United States and not yet registered in the destination country. The patient was receiving care at a private hospital with an established named-patient-import process and an engaged pharmacy director.

The constraint. The specific product was in a limited-distribution network in the United States that did not ordinarily supply cross-border cases. The hospital's previous broker had been unable to secure supply on predictable terms, and the P&T committee was unwilling to open an authorisation until a supply cadence could be demonstrated.

The coordination posture. Reserve Meds was introduced on a recommendation from a peer institution. We engaged the pharmacy director first, walked the P&T committee through our sourcing, documentation, and cold-chain posture in a single briefing, and then opened the patient-level file once the institutional prerequisites were met.

What we did. We confirmed access through the US manufacturer's limited-distribution programme on the appropriate terms for a cross-border named-patient case. We provided the hospital with a full sourcing and DSCSA documentation pack for review before the first shipment. We ran the named-patient authorisation in parallel with the first procurement so that the first dose landed within the treating physician's intended initiation window. We delivered to the hospital pharmacy with a cold-chain log accepted without excursion.

The handoff. The treating rheumatologist managed administration, titration, and monitoring. The hospital pharmacy carried dispensing under its ordinary SOP. Reserve Meds remained on the cycle as the sourcing and regulatory partner, with quarterly reviews of the authorisation and procurement plan against any changes in the underlying regulatory environment. The engagement has since extended to a second indication within the same institution.

Reviewed 2026-04-22 by Reserve Meds's AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.